Oral ciclopirox for skin sensitivity in CEP
Part of Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial tests an oral medication called ciclopirox (ATL-001) to see if it can reduce skin sensitivity to sunlight in adults with CEP. It aims to improve the skin lesions caused by this rare disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years of age or older.
- You must have a confirmed diagnosis of Congenital Erythropoietic Porphyria (CEP).
- If you are a woman who could become pregnant, you must not be pregnant or breastfeeding, and you must agree to use two reliable forms of birth control.
- If you are a man with a partner who could become pregnant, you must agree to use effective birth control and not donate sperm.
- You cannot have other skin conditions that cause sun sensitivity, like solar urticaria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication, PORT-77, to reduce pain and sensitivity to sunlight in people with EPP or XLP. It may help those who experience symptoms shortly after sun exposure.
This study tracks how your body reacts to sunlight if you have erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP)—rare genetic conditions that cause painful skin reactions to sun exposure. Researchers will use special devices and daily logs to better understand your symptoms and how light affects your skin.
This program provides access to an experimental drug called bitopertin, which may help reduce the severe light sensitivity and pain caused by EPP or XLP. It's for people aged 12 and older who have not had success with other treatments.
This study tests an oral medication called erlotinib (an EGFR inhibitor) to see if it can reduce the skin symptoms of keratinopathies like epidermolytic ichthyosis, epidermolytic palmoplantar keratoderma, and pachyonychia congenita. The goal is to improve skin condition and quality of life.
This trial studies how safe and well bitopertin works over the long term for people with EPP. It mainly includes people who already finished an earlier bitopertin study, to keep tracking side effects and overall progress.
This trial tests a compound that affects certain chemicals in your body (purines) to see if it helps people with pseudoxanthoma elasticum (PXE), a rare genetic condition affecting skin, eyes, and blood vessels.
Hear when a new Congenital Erythropoietic Porphyria (CEP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.